系统性轻链与转甲状腺素蛋白淀粉样变性的治疗进展与未来方向
该综述指出系统性淀粉样变性已从无获批疗法的罕见致死病变为高度可治,2018年以来有六种新疗法获批用于ATTR型,2021年达雷妥尤单抗联合方案获批用于AL型,双特异性T细胞衔接器在复发AL中显示空前疗效。文章从分子机制视角综述流行病学、病理生理、诊断及已获批和在研疗法,并讨论治愈挑战。
要点
- 对临床表现提示者应早期怀疑系统性淀粉样变性,尽快组织诊断并分型蛋白。
- 2018年以来已有六种新疗法获批用于ATTR淀粉样变性。
- 达雷妥尤单抗联合环磷酰胺、硼替佐米和地塞米松于2021年获批治疗AL淀粉样变性。
核心结论
- 系统性淀粉样变性已成为高度可治疾病,早期怀疑、快速组织诊断分型并及时启动主动治疗是关键。
- 针对转甲状腺素蛋白错误折叠聚集的基础发现推动了ATTR新药研发,免疫治疗在复发AL中展现空前疗效。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 2018年以来有六种新疗法获批用于转甲状腺素蛋白(ATTR)淀粉样变性。
- 达雷妥尤单抗联合环磷酰胺、硼替佐米和地塞米松于2021年获批用于轻链(AL)淀粉样变性。
- 双特异性T细胞衔接器等高效免疫治疗在复发AL淀粉样变性临床试验中显示出空前疗效。
关键数值与推荐
- 对临床表现提示系统性淀粉样变性的个体应早期提高怀疑,随后快速组织诊断、适当蛋白分型并及时开始主动治疗。
临床怎么用
- 临床遇提示性表现应早期怀疑系统性淀粉样变性,尽快完成组织诊断与蛋白分型。
- 确诊后应参照已获批方案及时启动主动治疗,ATTR与AL型分别有相应获批疗法。
局限性
- 摘要未报告综述的检索范围与纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific discoveries regarding the molecular mechanisms of transthyretin misfolding and aggregation have driven the development of drugs for the treatment of transthyretin (ATTR) amyloidosis, with six novel therapies approved since 2018. The combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone was approved for the treatment of light chain (AL) amyloidosis in 2021. Since then, highly effective immunotherapies, such as bispecific T-cell engagers, have been tested in clinical trials in patients with relapsed AL amyloidosis, with unprecedented efficacy. Thus, suspicion of systemic amyloidosis should be raised early in individuals with a suggestive clinical presentation, followed by rapid tissue diagnosis, with appropriate protein typing and prompt commencement of active therapy. These rapid and exciting therapeutic advancements set the stage for this Review on the epidemiology, pathophysiology, and diagnosis of systemic amyloidosis. Through the lens of the molecular mechanisms underlying amyloidosis pathogenesis, we will focus on approved and investigational therapies. We also discuss future directions and challenges concerning a cure for patients with AL or ATTR amyloidosis.
引用
- Bianchi G, Sanchorawala V, Wechalekar A, et al. Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions. Lancet. 2026. PMID: 42419329. doi:10.1016/S0140-6736(26)00302-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。